Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

488
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
488
Cancer Vaccines01:30

Cancer Vaccines

342
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
342
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Expression, Purification And Characterization Of A Novel Triple Fusion Protein Developed For The Immunotherapy Of Survivin Positive Cancers.
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Expression, Purification And Characterization Of A Novel Triple Fusion Protein Developed For The Immunotherapy Of Survivin Positive Cancers.

Related Experiment Video

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

14.7K

Expression, purification and characterization of a novel triple fusion protein developed for the immunotherapy of survivin positive cancers.

Ambreen Rashid1, Mohammad Azad2, Anuja Krishnan3

  • 1Talwar Research Foundation, E-8, Neb Valley, New Delhi, 110068, India; Jamia Hamdard, Hamdard Nagar, New Delhi, 110062, India.

Protein Expression and Purification
|October 13, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

A novel triple fusion protein targets Survivin, a protein overexpressed in many cancers. This engineered vaccine enhances anti-cancer immune response for targeted immunotherapy.

Keywords:
CancerDendritic cellsImmunotherapySurvivin

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.2K
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.2K

Related Experiment Videos

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

14.7K
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.2K
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.2K

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • Survivin is a key inhibitor of apoptosis, highly expressed in various cancers but minimally in normal tissues.
  • This differential expression makes Survivin a significant target for cancer diagnosis, prognosis, and therapeutic development.
  • Targeted cancer immunotherapy aims to leverage the immune system to combat cancer by targeting specific tumor antigens like Survivin.

Purpose of the Study:

  • To develop a novel triple fusion protein for a prospective vaccine against Survivin.
  • To engineer a targeted delivery system for enhanced antigen processing by dendritic cells.
  • To evaluate the efficacy of the fusion protein in eliciting an anti-Survivin immune response for cancer immunotherapy.

Main Methods:

  • Synthesized a gene encoding human Survivin, heat-labile enterotoxin of Escherichia coli (LTB), and a single-chain variable fragment (scFv) targeting the DEC205 receptor.
Vaccine
  • Expressed the triple fusion gene as a recombinant protein (DC/Survivin-LTB) using a bacterial expression vector.
  • Purified the ~60 kDa recombinant protein from inclusion bodies and characterized it using Western blot, circular dichroism, fluorescence spectroscopy, and mass spectrometry.

    • Main Results:

    • Successfully synthesized and expressed the triple fusion protein, DC/Survivin-LTB.
    • Purified and characterized the recombinant protein, confirming its structure and integrity.
    • The molecularly adjuvanted fusion protein demonstrated a stronger anti-Survivin immune response compared to Survivin protein alone, indicating enhanced antigen processing via dendritic cell targeting.

    Conclusions:

    • The developed DC/Survivin-LTB fusion protein serves as a promising candidate for a cancer vaccine.
    • This novel approach facilitates targeted delivery to dendritic cells, enhancing antigen presentation and immune response.
    • The fusion protein holds potential for effective application in active and passive immunotherapies against Survivin-expressing cancers.